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Aims The sympathetic nervous system plays a central role in cardiac growth but its overstimulation is
associated with increased mortality in patients with chronic heart failure. Pre-synaptic a2-adrenocep-
tors are essential feedback regulators to control the release of norepinephrine from sympathetic
nerves. In this study we tested whether a deletion polymorphism in the human a2C-adrenoceptor
gene (a2CDel322–325) affects progression of heart failure in patients with dilated cardiomyopathy
(DCM).
Methods and results We genotyped and phenotyped 345 patients presenting with DCM in the heart
transplant unit of the German Heart Institute, starting in 1994. Patients were treated according to
guidelines (99% ACEI, 76% b-blockers) and were followed until December 2002 or until a ﬁrst event
[death, heart transplantation, or implantation of a left ventricular assist device (LVAD) for a life-
threatening condition] occurred. Mean follow-up time was 249 weeks (4.9 years) in event-free patients
and 104 weeks (2 years) in patients with events. During follow-up, 51% of the patients exhibited an
event: death (18%), implantation of LVAD as bridging for transplantation (7%), or heart transplantation
(25%). By Kaplan–Meier analysis, DCM patients with the deletion variant Del322–325 in the a2C-adreno-
ceptor showed signiﬁcantly decreased event rates (P ¼ 0.0043). Cox regression analysis revealed that
the presence of the deletion was associated with reduced death rate (relative risk: 0.129, 95% CI:
0.18–0.9441, P ¼ 0.044) and event rates (relative risk: 0.167, 95% CI: 0.041–0.685, P ¼ 0.012).
Conclusion a2C-Adrenoceptor deletion may be a novel, strong, and independent predictor of reduced
event rates in DCM patients treated according to guidelines.
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Introduction
Activation of the sympathetic nervous system is an essential
mechanism to adapt cardiac function to increased demand.
However, in patients with chronic heart failure, sympathetic
overactivity is associatedwith accelerated disease progression
and increased morbidity and mortality.1,2 b-Adrenoceptor
antagonists exert a beneﬁcial long-term effect on the survi-
val of patients with congestive heart failure.3–5
The activity of the sympathetic system is controlled
by inhibitory pre-synaptic a2-adrenoceptors.
6 They are
involved in the inhibition of neurotransmitter release, regu-
lation of blood pressure, regulation of insulin release and
lipolysis, and a broad spectrum of other physiological func-
tions.7,8 Molecular cloning has led to the identiﬁcation of
the three a2-adrenoceptor subtypes, a2A, a2B, and a2C.
9
Two of these receptors, a2A and a2C, predominantly
control norepinephrine release from sympathetic nerves as
shown by studies in gene-targeted mice.7 Several functional
differences were identiﬁed between pre-synaptic a2A- and
a2C-receptor subtypes.
7,10 In mouse atria, the a2A-subtype
inhibited norepinephrine release at high stimulation fre-
quencies, whereas the a2C-receptor operated at lower
levels of sympathetic nerve activity.7 In addition, a2C-
adrenoceptors are required as feedback regulators of
catecholamines in adrenal chromafﬁne cells.11
The a-adrenergic receptors in the myocardium are
required for physiological cardiac growth processes and
have been shown to transmit growth signals in double-
knockout mice.12 In addition, they contribute to feedback
control of sympathetic transmitter release and their del-
etion causes increased circulating catecholamine levels,
which will lead to increased b-adrenergic stimulation,
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development of cardiac hypertrophy and ﬁbrosis, and
increased mortality from heart failure after left ventricular
pressure overload.13 The clinical relevance of these ﬁndings
was highlighted by the identiﬁcation of a four-amino acid
deletion polymorphism of the human a2C-adrenoceptor
(a2CDel322–325), which was associated with decreased
G-protein-coupling of this receptor variant.14 Human beings
carrying this mutation may be more prone to sympathetic
overstimulation than people with the fully functional a2C-
adrenoceptors if b-adrenergic receptors are unblocked.
However, in the presence of b-blockade, the effects of
a-adrenoceptors on myocardial growth may dominate. The
present study was undertaken to determine the effect of
the a2CDel322–325 variant on mortality and event-free
survival in a cohort of patients with dilated cardiomyopathy
(DCM) treated according to present guidelines, including a
high percentage of b-blockade and use of antibradycardiac
and antitachycardiac pacemakers in almost half of the
patients.
Methods
Patients
Patients were recruited from the transplant unit of the German
Heart Institute from April 1994 until August 1999 through the enrol-
ment of all eligible patients who gave informed consent. Criteria for
enrolment were an age of 20–79 years and a diagnosis of DCM. All
patients had been referred to the transplant unit for evaluation
for heart transplantation. All patients had undergone cardiac cathe-
terization, and diagnosis of DCM was based on exclusion of signiﬁ-
cant coronary artery disease, primary hypertensive heart disease,
primary valvular disease, hypertrophic obstructive and non-obstruc-
tive cardiomyopathy, and myocarditis. All patients were accepted
for transplantation and they were treated according to guidelines,
including the use of ACE-inhibitors, b-blockers whenever possible,
and AICD-implantation in the case of malignant arrhythmia.
Exercise testing with measurement of cardiopulmonary function
by oxygen uptake (spiroergometry) was introduced as a routine
procedure in 1998; therefore, data are only available in a subgroup
(n ¼ 18). Patients were followed up in 3 or 6 month intervals in the
transplant unit up until December 2002 or until one of the following
endpoints occurred: heart transplantation, death, or implantation
of LVAD. Listing with normal or high priority for transplantation
was made according to the clinical condition. Implantation of an
LVAD was used as bridging to transplantation if the patient’s con-
dition was judged to be deteriorating in an acutely life-threatening
manner and a donor organ was not available. All patients gave
informed written consent for genotyping. The rules of WHO were
followed throughout the study.
Statistics
The SPSS program (version 11.5) was used for statistical analysis.
Categorical data were compared by x2 testing. Survival was ana-
lysed using Kaplan–Meier curves and tested by the log-rank test.
To test for confounding factors, we also performed Cox regression
analysis. We included in the Cox regression models the a2C poly-
morphism a priori and factors known to have an inﬂuence on the
endpoint death or the combined endpoint death/LVAD implan-
tation/heart transplantation (age, age at diagnosis of cardiac
disease, gender, body mass index, blood pressure, NYHA classiﬁ-
cation, ejection fraction measured by echocardiography, and pre-
sence of malignant ventricular arrhythmia).
Besides all cause mortality, we used the combined endpoint
(death/LVAD implantation/heart transplantation), because the
occurrence of death was assumed to be frequently prevented by
LVAD or urgent transplantation. The combined endpoint thus
better describes the occurrence of end-stage cardiac disease.
Results
Characterization of patients
A total of 345 patients were included in this study.
Characterization of the patients is shown in Tables 1–3:
Table 1 Baseline characteristics of the study population at study entry
Characteristic All patients Surviving
patients
without events
Patients with
event (death,
HTx, LVAD)
P
n (male/female) 345 (288/57) 170 (144/26) 175 (144/31)
Mean follow-up (weeks) 178.0+ 144.0 249.0+ 145.7 104.3+ 99.0 ,0.05
Age at onset of disease (years) 45.3+ 10.0 44.1+ 10.9 46.4+ 8.9 0.023
Age at study entry (years) 48.7+ 10.2 47.1+ 11.1 50.3+ 9.0 0.02
Age at event (years) 51.4+ 10.4 — 51.4+ 10.4
NYHA class 2.4+ 0.7 2.2+ 0.70 2.7+ 0.70 ,0.001
Heart transplantation (n) 0 63
LVAD (n) 0 25
Death (n) 0 87
BMI (kg/sqm) 26.4+ 3.8 26.7+ 4.0 26.0+ 3.7 n.s.
LVEDD (mm) 71.9+ 9.1 69.7+ 9.2 74.2+ 8.3 ,0.001
LVEF (%) 23.1+ 7.1 25.3+ 7.9 21.04+ 5.6 ,0.001
BP sys (mmHg) 122.3+ 19.9 126.6+ 20.6 117.2+ 17.8 ,0.001
BP dia (mmHg) 75.7+ 12.6 77.0+ 13.4 74.1+ 11.5 n.s.
HR (b/min) 86.0+ 17 83.8+ 16.6 87.8+ 17.7 0.023
PAPm (mmHg) 29.5+ 11.9 27.0+ 12.0 31.9+ 11.4 ,0.001
b-AR autoantibodies (U/L) 3.8+ 2.3 3.6+ 2.4 4.0+ 2.2 n.s.
Sinus rhythm (n, %) 244 (70.7) 126 (74.1) 118 (67.4) n.s.
Malignant ventricular arrhythmia (n, %) 130 (37.7) 56 (32.9) 74 (42.3) 0.017
Data are mean+ SD. b-AR, b-adrenoreceptor; BP, blood pressure; HR, heart rate; PAPm, pulmonary artery pressure mean.
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98.26% patients were Caucasians of central European origin
and the remaining six were of Turkish origin; 16.5% were
women. Patients exhibited severely impaired systolic
cardiac function, as indicated by reduced left ventricular
ejection fraction (LVEF) and ventricular dilatation (LVEDD),
and increased pulmonary artery pressure (Table 1).
Malignant ventricular arrhythmia deﬁned as non-sustained
or sustained VT or ventricular ﬁbrillation was identiﬁed by
24-h ECG in about one-third of the patients.
Mean follow-up was 249 weeks (4.9 years) in event-free
patients and 104 weeks (2 years) in patients with events.
During follow-up, 51% of patients exhibited an event:
death (18%), heart transplantation (25%), or implantation
of LVAD as bridging to transplantation (7%) (Table 1).
Comparison of patients by genotype indicated that differ-
ences between deletion carriers (a2CDel322–325) and
patients without deletion existed in cardiopulmonary func-
tion measured by spiroergometry (Table 2). In a subgroup
that was studied by spiroergometry, deletion carriers had a
signiﬁcantly higher oxygen uptake and greater ventilatory
efﬁciency (lower slope of the ratio ventilation/VCO2), indi-
cating better cardiopulmonary function. In this subgroup,
all other clinical parameters, including EF and LVEDD, did
not differ signiﬁcantly between a2CDel322–325 carriers and
wild types (data not shown).
Medical treatment and use of pacemakers
Starting at the ﬁrst visit in the transplant unit, the therapy
was optimized according to guidelines leading to treatment
with ACEI in 99% of patients, b-blockers in 76%, and aldos-
terone antagonists in 60% of patients. As a b-blocker, the
b1-selective agent metoprolol was generally used. At pres-
entation, 25% of patients were treated with a b-blocker
which was subsequently, if no contraindications were
found, uptitrated to the highest individually possible dose,
resulting in the use of .100 mg metoprolol in 55%.
Arrhythmia was systematically monitored by 24-h ECG.
Forty-seven per cent of the patients received a pacemaker,
15% an antibradycardia system, and 32% an antitachycardia
system or deﬁbrillator (AICD). Documented malignant
arrhythmia or cardiac syncope was a prerequisite for AICD
implantation. If necessary, oral treatment with amiodarone
was added to the regimen.
Genotypes and allele frequencies
Patients heterozygous for a2CDel322–325 were 7.2%. No
a2CDel homozygote patients were detected. The frequency
of the wild-type allele was 96.38% and for a2CDel, it was
3.62%. All genotype distributions were in Hardy–Weinberg
equilibrium (Table 3).
Outcome analysis
Kaplan–Meier analysis showed survival differences with
respect to the a2CDel adrenoceptor polymorphism
(Figure 1A). Cox regression analysis demonstrated that the
presence of the a2CDel adrenoceptor variant reduced the
risk for death on the waiting list for cardiac transplantation
to 0.129 (95% CI 0.18–0.94). The effect of the a2CDel poly-
morphism on mortality was independent of age, duration
of cardiac disease, gender, body mass index, blood pressure,
NYHA classiﬁcation, ejection fraction measured by echocar-
diography, and presence of malignant ventricular arrhyth-
mia. Survival was also independently affected by left
ventricular systolic function (LVEF) (Table 4, column 5).
Kaplan–Meier analysis for the combined endpoint death/
LVAD implantation/heart transplantation likewise revealed
a signiﬁcant impact (P ¼ 0.044) of the a2CDel polymorphism
Table 3 Genotype distributions and allelic frequency of the
a2CDel322 variant
Genotype Allelic frequency
a2CDel322–325/
a2CDel322–325
0% a2CDel322–325 3.6%
a2CDel322–325/WT 7.2%
WT/WT 92.8% WT 96.4%
Hardy–Weinberg equilibrium was present. WT, wild type.
Table 2 Basic demographics and selected clinical data at study entry
Characteristic All patients Patients without
a2C-adrenoceptor
deletion
Patients with
a2C-adrenoceptor
deletion
P
n (male/female) 345 (288/57) 320 (267/53) 25 (21/4) 0.91
Age at onset of cardiac disease (years) 45.3+ 10.0 45.6+ 9.8 41.5+ 11.44 0.97
Age at study entry (years) 48.7+ 10.2 49.047+ 9.9324 44.615+ 12.8073 0.103
NYHA class 2.4+ 0.7 2.23+ 0.718 2.23+ 0.69 0.642
VO2 max
a (maximal oxygen uptake/
min  kg BW) (number of patients)
15.49+ 4.974 15.1+ 4.8 (n ¼ 111) 21.6+ 3.8 (n ¼ 7) 0.003
Slopeb (ventilation (L/min)/exhaled
CO2 (L/min)) (number of patients)
35.37+ 9.569 35.8+ 9.8 (96) 29.6+ 2.8 (7) 0.001
BMI (kg/sqm) 26.4+ 3.8 26.4+ 3.9 25.4+ 3.4 0.141
LVEDD (mm) 71.9+ 9.1 72.08+ 9.013 70.44+ 10.296 0.446
LVEF (%) 23.1+ 7.1 22.9+ 7.0 25.5+ 8.4 0.169
BP sys (mmHg) 122.3+ 19.9 121.72+ 19.855 128.80+ 19.109 0.097
BP dia (mmHg) 75.7+ 12.6 75.45+ 12.331 79.20+ 15.389 0.245
Malignant ventricular arrhythmia (n, %) 113 (32.7) 109 (34.1) 4 (16) 0.064
Continuous data are given as mean+ SD.
456 V. Regitz-Zagrosek et al.
on event-free survival (Figure 1B). Cox regression revealed
that relative risk for carriers of the a2CDel adrenoceptor
variant was reduced to 0.167 (95% CI: 0.041–0.685,
P ¼ 0.012) (Table 4). Event-free survival was also indepen-
dently affected by NYHA classiﬁcation, left ventricular sys-
tolic function (LVEF), and left ventricular size (LVEDD)
(Table 4, column 8).
Discussion
In the present study we demonstrate for the ﬁrst time that
genetic variation in the a2C-adrenoceptor gene
(a2CDel322–325) is independently associated with survival
and absence of events in patients with severe heart failure
due to dilated DCM. Statistical analysis was done for two
endpoints: death and the combined endpoint of death and
transplantation and implantation of an LVAD. As the occur-
rence of death was probably assumed to be frequently pre-
vented by LVAD or urgent transplantation, the combined
endpoint gives a more realistic estimate of the occurrence
of end-stage cardiac disease.
It is generally known that the number of patients may be a
potential study limitation in genetic association studies. Our
cohort of advanced DCM patients represents the largest poss-
ible cohort of our centre of well-characterized DCM patients
with a long follow-up. The principle ﬁndings seen in the
initial Kaplan–Meier analysis remained statistically signiﬁcant
after consideration (by Cox regressions) of well-known
confounding factors. The relevance of known independent
confounders such as LVEF, NYHA class, and left ventricular
size was conﬁrmed in our study. This clearly suggests that
the a2C-adrenoceptor gene (a2CDel322–325) polymorphism
represents an important and independent genetic factor
that determines survival in patients with advanced DCM.
However, it is now well recognized that genetic association
studies need conﬁrmation in independent populations for a
variety of reasons that will not be discussed here.
Interested reader may refer to the work of Colhoun et al.15
We would be happy if our study could form the rationale for
a larger multi-centre study. This is especially important, as
the current study strongly suggests the use of the a2C-adreno-
ceptor gene (a2CDel322–325) polymorphism as an additional
factor for the determination of the priority of patients on
the waiting list for heart transplantation. Our data are thus
potentially of major clinical impact.
Norepinephrine and epinephrine induce multiple actions
in the cardiovascular system via six different a-adrenocep-
tor subtypes (a1A, a1B, a1D, a2A, a2B, a2C) and three differ-
ent b-receptor subtypes (b1,2,3,).
9 a1- and b-Adrenoceptors
may induce myocardial hypertrophy in both postnatal and
Figure 1 Kaplan–Meier analysis for mortality (A) or the combined endpoint (B): death, implantation of an LVAD, or heart transplantation. Four out of 25 patients
heterozygous for the deletion (a2CDel322–325) in the a2C-adrenoreceptor died, whereas 83 out of 320 patients without deletion in the a2C-adrenoreceptor died.
Only 6 of 25 patients heterozygous for a2CDel322–325 reached the combined endpoint death, LVAD implantation, or heart transplantation, whereas 169 out of 320
patients without deletion in the a2C-adrenoreceptor reached the combined endpoint. Curves were compared using the log-rank test.
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adult life, depending on pathophysiological conditions.
Studies in gene-targeted mice have shown that a-adreno-
ceptors are required for physiological growth during
normal postnatal cardiac development and for an adaptive
response to cardiac stress.12 In combination, a1- and b-adre-
noceptors contribute to the adaptation of heart rate and the
initiation of physiological and pathophysiological cardiac
hypertrophy.
Several lines of evidence support a link between the func-
tional a2C-Del322–325 adrenoceptor variant and activation
of the sympathetic nervous system. Deletion of four amino
acids in the third intracellular loop of the human a2C-recep-
tor (a2CDel322–325) leads to the impairment of G-protein-
coupling when this receptor variant is expressed in cell
lines in vitro.14 In mice, deletion of a-adrenoceptors
impairs feedback inhibition of catecholamine release. a2C-
Receptor-deﬁcient mice had elevated circulating catechol-
amines after transverse aortic constriction compared with
wild-type mice.13 Deﬁciency of a2C-receptors may thus
lead to increased activation of myocardial a1- and b-adreno-
ceptors. This may be responsible for initiating cardiac hyper-
trophy and failure if b1-adrenoceptors are unblocked.16,17
However, if b1-adrenoceptors are blocked, catecholamines
may predominantly stimulate growth processes via a1- and
b2-adrenoceptors.
As the effect of the a2CDel polymorphism modiﬁes the
activity of the adrenergic system, it may be speculated
that a2CDel patients may particularly beneﬁt from
b-blocker treatment. In our own previous study, we
observed a decreased cardiac function in Caucasian heart
failure patients carrying the a2CDel polymorphism who
were not treated with b-blockers or antitachycardiac pace-
makers.13,18 However, in the present study, 99% of patients
were treated with ACEI and 76% received b-blockers. More
than 50% of patients reached a dose of.100 mg metoprolol.
This may effectively inhibit b1-adrenergic overstimulation.
At the same time, a1- and b2 adrenoceptors are not inhib-
ited by metoprolol treatment. a1A/C and a1B are required
for physiological cardiac hypertrophy and their deletion is
associated with a worse prognosis in pressure overload.12
Thus, maintained stimulation of a1- and b2- adrenoceptors
in the presence of b1-adrenergic blockade may be the
basis for beneﬁcial effects of a2CDel322–325 in our cohort.
In our current study, we included patients with nearly
end-stage heart failure suffering from DCM and referred
for heart transplantation. As only patients with advanced
stages of heart failure and very low ejection fractions are
considered as candidates for heart transplantation, the
ejection fraction was below 30% and similar in all genotypes.
However, in our previously published study the inclusion cri-
teria were different. There, HF patients with an ejection
fraction of below 55% of different aetiologies and in diff-
erent stages of HF were included. Given that the
a2CDel322–325 deletion acts as a survival factor in DCM
patients, the deletion carriers with low EF would be
expected to accumulate in such a sample, as there is a
higher likelihood that patients without this deletion will
die. Such a selection bias may have contributed to the
results of the ﬁrst study. Indeed, some clinical ﬁndings in
the present study point towards a potential survival advan-
tage for the deletion carriers. Deletion carriers had a
highly signiﬁcant greater maximal oxygen uptake and
better ventilatory efﬁciency. This difference is highly signiﬁ-
cant even though only data from a subgroup are available.
Thus it seems that deletion carriers have better cardiopul-
monary exercise tolerance in the presence of comparable
impairment of left ventricular function. However, exercise
tolerance is one of the best predictors of survival.
Therefore, this survival advantage in the deletion carriers
may be the focus of further investigations.
Patients with DCM are susceptible to arrhythmias caused
by a-adrenergic overactivation, and high-dose b-blocker
therapy may induce bradycardia. Both risks were limited
in our cohort by close follow-up for arrhythmias and
by medical antiarrhythmic treatment, preferentially with
amiodarone and with regular use of antibradycardiac and
antitachycardiac pacemakers and deﬁbrillators. The latter
were strictly used only if malignant arrhythmia was
Table 4 Cox proportional hazards analysis of factors predicting death or the combined endpoint: death, implantation of an LVAD, or heart
transplantation in our entire study population
Risk factor Death Death, LVAD, or heart transplantation
Relative risk 95% CI P-value Relative risk 95% CI P-value
Heterozygous for a2C2
Del322–325 deletion
Yes 1/7.75 ¼ 0.129 0.18–0.9441 0.044 1/5.99 ¼ 0.167 0.18–0.944 0.013
Gender Male 0.889 0.417–1.894 0.761 1.222 0.736–2.029 0.439
Age (years) Per additional year 1.045 0.978–1.116 0.194 1.037 0.989–1.086 0.130
Age at diagnosis of
heart disease
Per additional year 0.987 0.923–1.056 0.708 0.979 0.933–1.027 0.388
NYHA classiﬁcation Per additional NYHA
class
1.311 0.908–1.895 0.149 1.514 1.178–1.945 0.001
Ejection fraction Per addition % of EF 0.947 0.904–0.992 0.021 0.960 0.929–0.992 0.016
Body mass index Per additional
BMI point
0.978 0.913–1.048 0.526 0.963 0.916–1.012 0.135
Left ventricular end-
diastolic diameter
Per additional mm of
LVEDD
1.027 0.997–1.058 0.076 1.023 1.001–1.045 0.037
Systolic blood pressure Per additional mmHg 0.992 0.978–1.006 0.251 0.992 0.982–1.002 0.137
Presence of malignant
ventricular arrhythmia
Yes 0.849 0.500–1.442 0.545 1.100 0.760–1.592 0.613
458 V. Regitz-Zagrosek et al.
documented in the ECG, or a syncope was strongly believed
to be due to arrhythmia. Therefore, the use of AICDs reﬂects
the presence of life-threatening arrhythmia quite well. The
number of malignant arrhythmia showed a trend towards
lower values in the deletion carriers, but the difference
did not achieve statistical signiﬁcance and can therefore
not contribute to a better understanding of the effect of
the deletion.
For still unknown reasons, the prevalence of the
a2CDel322–325 polymorphism is higher in black than in
white Americans.19 Higher allele frequencies were observed
in black heart failure patients (61%) in comparison with con-
trols (41%),19 but comparable differences were not observed
in Caucasians and no data are available for Turkish patients.
Interestingly, it is generally accepted that black heart
failure patients respond particularly well to b-blockers.
Thus, further studies may test the hypothesis that the pre-
sence of the a2CDel322–325 is associated with a greater
response to b-blockers. We cannot conﬁrm this hypothesis,
as the number of patients treated with b-blockers increased
continuously from 25% at presentation to 76% during the
study period. Indeed, b-blockers were started in all patients
without contraindications and were titrated up and contin-
ued in the highest individually acceptable dose. Thus, we
cannot deﬁne meaningful and comparable b-blocker-
treated and non-b-blocker-treated subgroups.
In conclusion, our data suggest that Caucasian patients
with the a2C322–325 deletion do have a functional advan-
tage in the presence of an equally impaired left ventricular
function in comparison with the ‘wild-types’. The functional
beneﬁt was observed under intensive medical and device
therapies in the present study. More data are needed to
analyse the effect of this polymorphism on the clinical
course of patients with DCM and its implications for therapy.
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